Staging preview: health content pending qualified review
D2C Peptides

Dosage information

DSIP dosage

No human dose of DSIP is established, and no approved label exists.1 Published human studies gave it intravenously, most often 25 or 30 nmol/kg, and FDA found no study of injection under the skin.12 The doses on this page come from those studies and from animal work, and they are not guidance for people.

This page summarizes published sources for information only. It is not medical advice and does not tell anyone to use a product. Questions about your own health belong with a licensed clinician. For questions about an order or a product, contact us.

No human dose is established

DSIP has no FDA-approved label, so there is no labeled dose, schedule or route.1 FDA evaluated a proposed 1 mg/mL injection under the skin, but found no study supporting effectiveness by that route and no safety data for it.1 Across published studies, FDA counted 209 people given intravenous doses of 25 to 150 nmol/kg, for 1 to 15 days.1 Every dose below comes from a published study and is listed for context only.

Doses used in human studies

Doses are written per kilogram of body weight. FDA's summary gives 25 nmol/kg as 21.23 micrograms per kilogram.1

Study People Route and dose Schedule
Healthy volunteers, 1981 6 IV infusion, 25 nmol/kg8 One morning infusion, given over 20 minutes per FDA's summary1
Chronic insomnia, 1981 6 middle-aged adults IV, 25 nmol/kg9 Once or twice over 3 test nights (randomized crossover), each over 4 minutes right before bedtime1
Chronic insomnia, Monti 1987 6 IV, 25 nmol/kg or placebo10 4 nights, double-blind crossover
Chronic insomnia, Bes 1992 16 IV, 25 nmol/kg11 Afternoons before nights 3, 4 and 5
Chronic insomnia, 1986 18 IV, 30 nmol/kg2 6 doses in one week
Chronic insomnia, 1987 14 middle-aged adults IV, 30 nmol/kg112 7 nights in a row
Alcohol and opiate withdrawal, 1984 107 inpatients IV, 25 nmol/kg1 Up to 6 injections a day for up to 6 days
Opioid withdrawal, 1998 7 IV, 35 nmol/kg1 Fixed schedule over 7 days
Chronic pain episodes, 1984 7 IV, dose not stated in the abstract13 5 days in a row, then 5 injections every 48 to 72 hours
Stress hormones, healthy men, 1989 11 IV, 25 nmol/kg or saline14 Single dose, randomized crossover
Growth hormone, healthy women, 1993 5 IV, 25 micrograms/kg over 30 minutes15 Single dose
Stress hormones, healthy men, 1995 10 in hormone-challenge (CRH) tests, 10 in a meal test IV infusion, total 3 or 4 mg16 One infusion against placebo, about 2 hours in the CRH tests
Isoflurane anesthesia, 2009 12 women given DSIP (12 more given saline) IV bolus, 25, 50 or 100 nmol/kg7 Two doses: one awake, one under anesthesia

How the injections were given

Speed of infusion mattered in the early work.171 Researchers reported in 1983 that slow injection proved essential, with sleep starting about 1 hour after injection.17 FDA's summary adds that, in healthy volunteers, DSIP was completely ineffective when infused over 1 minute, and total sleep time rose most with infusions over 4 to 8 minutes.1 DSIP also clears fast: FDA reports a plasma half-life of 8 minutes, with blood enzymes cutting it into shorter peptides.1

These details matter when reading claims about other routes. The studies that reported sleep effects used timed intravenous infusions in sleep laboratories. No study has tested whether those results hold for injection under the skin or for nasal sprays, and FDA found human data only for intravenous use.1

Doses used in animal studies

  • Rabbits, 1977: synthetic DSIP infused into the brain ventricles increased delta and spindle EEG patterns.18
  • Rats, intravenous: 30, 40 or 80 nmol/kg raised EEG delta-wave power between 1 and 4.5 hours after the injection.1
  • Rats, into the brain ventricles: 6 nmol/kg lengthened sleep, and the opioid blocker naloxone prevented that effect.1
  • Dogs, intravenous: a 100 micrograms/kg bolus was used to show DSIP passing into the cerebrospinal fluid.19

Animal doses are not human doses, and none of these studies was designed to find a dose for people.

Read the full DSIP profile, the safety record in DSIP side effects, and what the studies found in DSIP benefits and uses. General background on study doses and units is in Peptide dosage basics.

More on DSIP

  • DSIP side effects

    Side effects of DSIP as reported in clinical trials and published studies, with links to the full profile. Reviewed by a qualified reviewer.

  • DSIP benefits and uses

    What published sources report about DSIP and its uses, with the evidence level of each finding. No promises.

DSIP in the store

DSIP for sale: strengths, stock and shipping are on the product page.

For research use only. Not for human or veterinary use. Read the research use policy.

Frequently asked questions

How long can I take DSIP for?

No safe duration has been established for anyone.1 Published human studies lasted 1 to 15 days, and FDA found no information on benefit with long-term use.1 FDA also calls safety for long-term intermittent use insufficiently characterized.1 In the early insomnia studies, effects were reported to build up, with sleep structure normalizing after four injections, but those studies were small and supervised.3

How to use DSIP spray?

No approved instructions exist for a DSIP nasal spray, and none of the studies reviewed here gives a nasal dose.1 FDA found US clinics and retailers marketing DSIP sprays, yet all the human data in its 2026 review came from intravenous use.1 The only nasal report found, a 2001 letter, has no published abstract, so its dose is not known.4 The DSIP listed in this store is a freeze-dried vial for lab research, not a spray.

Can DSIP be taken by mouth?

There is no evidence that it works by mouth.51 In a lab model of the human gut lining (Caco-2 cells), DSIP was broken down quickly, with 8.2% left after 2 hours, and none of it crossed the cell layer.5 No oral dose appears in the human studies FDA reviewed, which used intravenous injection only.1

Did higher doses of DSIP work better?

Not in a simple way.6 In rats, intravenous doses of 30, 40 and 80 nmol/kg raised delta-wave power, with larger effects at higher doses.1 But a 1984 review reports a U-shaped activity curve for both the dose and the infusion time, so more did not reliably mean more effect.6 In a 2009 trial in 12 women under isoflurane anesthesia, DSIP at 25 to 100 nmol/kg made anesthesia lighter, not deeper, as measured by the bispectral index.7

Written by D2C Peptides Editorial Team.

Pending qualified review.

Updated .

Sources

  1. FDA Briefing Document, PCAC July 23-24, 2026: Emideltide-Related Bulk Drug Substances (dated 5/11/2026). U.S. Food and Drug Administration, 2026.
  2. Efficacy of DSIP to normalize sleep in middle-aged and elderly chronic insomniacs (Schneider-Helmert). European Neurology (abstract via PubMed, NLM), 1986.
  3. DSIP in insomnia (Schneider-Helmert). European Neurology (abstract via PubMed, NLM), 1984.
  4. Intranasal administration of delta sleep-inducing peptide increases P300 (Hruz et al.; letter). Journal of Clinical Psychopharmacology (citation via PubMed, NLM), 2001.
  5. Transport and metabolism of delta sleep-inducing peptide in cultured human intestinal epithelial cell monolayers (Augustijns and Borchardt). Drug Metabolism and Disposition (abstract via PubMed, NLM), 1995.
  6. Delta-sleep-inducing peptide (DSIP): a review (Graf and Kastin). Neuroscience and Biobehavioral Reviews (abstract via PubMed, NLM), 1984.
  7. Delta sleep-inducing peptide alters bispectral index, the electroencephalogram and heart rate variability when used as an adjunct to isoflurane anaesthesia (Pomfrett et al.). European Journal of Anaesthesiology (abstract via PubMed, NLM), 2009.
  8. Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior (Schneider-Helmert et al.). International Journal of Clinical Pharmacology, Therapy and Toxicology (abstract via PubMed, NLM), 1981.
  9. The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep (Schneider-Helmert and Schoenenberger). Experientia (abstract via PubMed, NLM), 1981.
  10. Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs (Monti et al.). International Journal of Clinical Pharmacology Research (abstract via PubMed, NLM), 1987.
  11. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study (Bes et al.). Neuropsychobiology (abstract via PubMed, NLM), 1992.
  12. Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia (Schneider-Helmert). European Neurology (abstract via PubMed, NLM), 1987.
  13. Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study (Larbig et al.). European Neurology (abstract via PubMed, NLM), 1984.
  14. Reduction of immunoreactive ACTH in plasma following intravenous injection of delta sleep-inducing peptide in man (Bjartell et al.). Psychoneuroendocrinology (abstract via PubMed, NLM), 1989.
  15. Delta sleep-inducing peptide administration does not influence growth hormone and prolactin secretion in normal women (Giusti et al.). Psychoneuroendocrinology (abstract via PubMed, NLM), 1993.
  16. Delta-sleep-inducing peptide does not affect CRH and meal-induced ACTH and cortisol secretion (Spath-Schwalbe et al.). Psychoneuroendocrinology (abstract via PubMed, NLM), 1995.
  17. Effects of DSIP in man. Multifunctional psychophysiological properties besides induction of natural sleep (Schneider-Helmert and Schoenenberger). Neuropsychobiology (abstract via PubMed, NLM), 1983.
  18. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proceedings of the National Academy of Sciences USA (PMC), 1977.
  19. Delta sleep-inducing peptide crosses the blood-brain-barrier in dogs: some correlations with protein binding (Banks et al.). Pharmacology Biochemistry and Behavior (abstract via PubMed, NLM), 1982.